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Marker rescue, the restoration of gene function by replacement of a defective gene with a normal one by
recombination, has been utilized to produce novel adeno-associated virus (AAV) vectors. AAV serotype 2
(AAV2) clones containing wild-type terminal repeats, an intact rep gene, and a mutated cap gene, served as the
template for marker rescue. When transfected alone in 293 cells, these AAV2 mutant plasmids produced
noninfectious AAV virions that could not bind heparin sulfate after infection with adenovirus dl309 helper
virus. However, the mutation in the cap gene was corrected after cotransfection with AAV serotype 3 (AAV3)
capsid DNA fragments, resulting in the production of AAV2/AAV3 chimeric viruses. The cap genes from several
independent marker rescue experiments were PCR amplified, cloned, and then sequenced. Sequencing results
confirmed not only that homologous recombination occurred but, more importantly, that a mixed population
of AAV chimeras carrying 16 to 2,200 bp throughout different regions of the type 3 cap gene were generated in
a single marker rescue experiment. A 100% correlation was observed between infectivity and the ability of the
chimeric virus to bind heparin sulfate. In addition, many of the AAV2/AAV3 chimeras examined exhibited
differences at both the nucleotide and amino acid levels, suggesting that these chimeras may also exhibit
unique infectious properties. Furthermore, AAV helper plasmids containing these chimeric cap genes were able
to function in the triple transfection method to generate recombinant AAV. Together, the results suggest that
DNA from other AAV serotypes can rescue AAV capsid mutants and that marker rescue may be a powerful, yet
simple, technique to map, as well as develop, chimeric AAV capsids that display different serotype-specific
properties.
Adeno-associated viruses (AAVs), members of the family
Parvoviridae and the genus Dependovirus, are small, nonenvel-
oped, single-stranded DNA viruses (reviewed in references 7
and 25). Distinct serotypes of AAV have been identified from
human and nonhuman primates, but only AAV serotype 2
(AAV2) has been extensively characterized and utilized in
gene therapy applications (5, 10–12, 14, 19, 24, 26, 29, 32, 33,
38, 47). Several properties of AAV2 make it a desirable gene
delivery system. Importantly, AAV2 has never been associated
with human disease, is considered nonpathogenic, and trans-
genes expressed from AAV2 vectors do not elicit a cell-medi-
ated immune response (7, 14, 18, 48). Recombinant AAV2-
based vectors produce long-term expression in the brains,
livers, muscles, and retinas of experimental animals (14, 21, 26,
48).
The AAV capsid is composed of three structural proteins
(VP1, VP2, and VP3), which are related to each other in that
they are generated from a single open reading frame (cap)
utilizing different start codons to express VP2 and 3 and an
alternative splice for VP1. VP3 is the smallest and the most
abundant capsid protein (80%), whereas the remaining pro-
teins, VP1 and VP2, are present in minor amounts (10% each)
(25). The structure of the capsids of several parvoviruses, in-
cluding human parvovirus B19, canine parvovirus, feline pan-
leukemia virus, Galleria mellonella densovirus (an insect par-
vovirus), Aleutian mink disease parvovirus, and minute virus of
mice, as well as the newly published structure for AAV2 is now
solved (1–3, 22, 37, 41, 50). The capsids of these parvoviruses
consist of 60 subunits; the smallest capsid protein makes up the
majority of the virion. These proteins have the -barrel motif
formed by eight  strands and have four prominent looped-out
regions. These looped-out regions constitute the majority of
the differences between the viruses, are exposed regions on the
capsid surface, and determine the biological properties of the
virus such as tissue tropism, antigenicity, host range, and bind-
ing to cellular receptors (8, 23).
A major limitation on the use of AAV2 is that it can infect
cells from a variety of tissues and organs (7, 25). The genera-
tion of AAV2 vectors that can selectively infect particular cells
would be advantageous to gene therapy protocols. Under-
standing of viral entry and binding to the cell is only known for
a few of the serotypes. The primary cellular receptor for AAV2
is heparan sulfate proteoglycan (HSP), a molecule found on
many cell types, which explains the broad tropism of AAV2
(40). Subsequent analyses have determined that the corecep-
tors for this virus are V5 integrin or human fibroblast
growth factor receptor 1 (27, 39). Recently, it has been estab-
lished that some AAV serotypes utilize receptors different
from AAV2. Serotypes 4 and 5 utilize sialic acid for efficient
transduction but differ in sialic acid linkage specificity, which
probably reflects that their tissue tropism is distinct from
AAV2 and each other (12, 13, 19, 43, 52). AAV1’s primary
cellular receptor is unknown but AAV1 transduces muscle
cells more efficiently than AAV2 (9, 47). Furthermore, AAV1
does not appear to bind to heparin columns (28), further sup-
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porting the notion that HSP is not a receptor for AAV1. AAV3
does bind heparin columns. Its DNA and amino acid sequence
is the most identical to that of AAV2 (33), exhibiting 82%
identity at the DNA level over the entire genome and, at the
amino acid level, the degree of homology between the capsid
regions of AAV2 and AAV3 is 87% (24).
Two approaches, chemically cross-linking bifunctional anti-
bodies (6) and genetic manipulation of the capsid gene, par-
ticularly in the looped-out regions of the capsid proteins (15,
31, 36, 46), have been utilized to retarget the AAV2 virus and
each method has its limitations (recently reviewed in reference
30). Recently, it has been proposed that the serotypes of AAV
represent a rare resource for the gene therapy community due
to their unique tropism and in vivo profile (30). Rabinowitz et
al. suggested a way to exploit the natural tropism of the sero-
types by domain swapping of proposed exposed surfaces of the
capsid regions of the serotypes. In the present study we de-
scribe a method complementary to domain swapping that takes
advantage of the degree of homology between the serotypes to
generate AAV2/AAV3 chimeras. In this system, defective
AAV2 mutants are rescued by wild-type AAV3 sequences
through homologous recombination. A collection of recombi-
nants carrying from 16 nucleotides (nt) to 2.2 kb were isolated
by this approach. All viable viruses regained the ability to bind
HSP, and this correlated 100% with infectivity in human cells.
This marker rescue approach can be extended to generate
chimeric viruses from all serotypes and should provide a quick
and simple method for mapping functional domains, as well as
generating novel AAV vectors with improved phenotypes for
efficient gene delivery.
MATERIALS AND METHODS
Cells and virus. HeLa and 293 cells were maintained at 37°C in a 5% CO2
atmosphere in Dulbecco modified Eagle medium (Sigma, St. Louis, Mo.) sup-
plemented with 10% heat inactivated fetal bovine serum and penicillin-strepto-
mycin. Adenovirus dl309 virus has been described previously (17).
Plasmids. The AAV3B plasmid was used in these studies (33). The plasmids
H/N3761 and H3766 (31) served as starting reagents for the construction of the
1n532 and 1n562 mutants. The H/N3761 and H3766 plasmids are versions of
psub201() (34) and pACG2 (20), respectively, which have an EcoRV in-frame
linker inserted at AAV2 nt 3761 and 3766, respectively. To construct the 1n562
mutant, the 3.7-kb fragment from the HindIII-EcoRV double digestion of H3766
was ligated to the 1.8-kb fragment from the HindIII-EcoRV digestion of
H/N3761. This created a unique amino acid at position 522 of VP1, which
continued to be out of frame until termination at amino acid 562. For the 1n532
mutant, the 1.8-kb fragment of the HindIII-EcoRV digestion of H3766 was
ligated to the 3.7-kb fragment from the HindIII-EcoRV double digestion of
H/N3761. This created a unique amino acid at position 522 of VP1, which
continued to be out of frame until termination at amino acid 532. The 1n562 and
1n532 clones did not contain the AAV2 terminal repeats, and each was cloned
into the psub201() background (34) by ligation of the 2.1-kb HindIII, XcmI
fragment from either the 1n562 or the 1n532 mutants to the 6.1-kb HindIII-XcmI
fragment of psub201(). Each clone was sequenced near the mutation site to
ensure that the clones were correct.
The pxr2AN shuttle vector was constructed in the following manner. The
pAAV2Cap plasmid (31) was modified via QuikChange mutagenesis to contain
unique AflII and NotI sites in the AAV2 genome at nt 2277 and 4657, respec-
tively, to generate the AAV2CapAN plasmid. The AAV2CapAN clone was
digested with SwaI and NotI to generate a 2,262-bp fragment, which was cloned
into the 5,189-bp fragment of pXR2 (28), which had been digested with NotI and
SwaI. The pxr2AN shuttle vector now contains unique AflII and NotI sites
flanking the capsid region.
PCR and sequencing methods. PCR fragments from the AAV3 capsid regions
were used for transfections and were amplified by the AAV3 primers AAV3Afl
(5-GGT GGG CTC TTA AGC CTG GAG TCC CTC AA-3) and AAV3Not
(5-AGT GCA CAG CGG CCG CAG TTC AAC TGA AAC G-3), which
amplify at AAV3 nt 2273 and 4471, respectively, to generate a 2.2-kb PCR
fragment. The amplification reactions consisted of an initial denaturation of 95°C
for 10 min, followed by 35 cycles of denaturation for 1 min at 95°C, annealing for
1 min at 59°C, and an extension for 2 min 30 s at 72°C. These PCRs were
performed with PfxTurbo polymerase (Life Technologies, Rockville, Md.).
AAV3 PCR products were sequenced to ensure correctness. The AAV3 PCR
capsid fragments were digested with DpnI to eliminate parental plasmid template
and were purified with Wizard PCR Preps (Promega, Madison, Wis.) prior to
transfection.
PCR of viral lysate was performed with either the AAV3Not and AAV3Afl
primer pair, described above or the AAV2Afl (5-GGT GGA AGC TTA AGC
CTG GCC CAC CAC CAC CA-3) and AAV2Not (5-AAT ACG CAG CGG
CCG CAG TTC AAC TGA AAC G-3) primer pair, which amplify at AAV2 nt
2266 and 4462. Both sets of PCR primers (AAV2 and AAV3) were engineered
to contain unique AflII and NotI fragments (the positions of the AflII and NotI
sites in the primers are underlined) that amplify a 2.2-kb fragment that can be
digested with AflII and NotI and cloned into the pxr2AN shuttle vector. The PCR
conditions for the AAV2 primer pair were identical to the conditions used for the
AAV3 primer pair that are described above. PCR of a viral lysate was performed
with Taq polymerase (Life Technologies). DNA from PCRs was cloned into the
pxr2AN shuttle vector prior to DNA sequence analyses.
Plasmid DNA was sequenced at the UNC-CH automated DNA sequencing
facility on a model 377XL-96 DNA sequencer or a 3100 genetic analyzer (both
from Applied Biosystems). The sequencing reactions were done by using the ABI
Prism BigDye terminator cycle sequencing ready reaction kit with AmpliTaq
DNA polymerase FS (Applied Biosystems).
The plasmids were sequenced with the 3 595 Bot primer (5-TTG TGT GTT
AAC ATC TGC GGT AGC TGC TTG-3), which anneals at nt 1790 of the
AAV2 capsid, or the AAV3Not, AAV3Afl, AAV2Afl, or AAV2Not primers
described above.
Transfection and cycling. A total of 1.8  106 293 cells were plated 18 h prior
to transfection in a 6-cm dish. 293 cells were transfected by using Superfect
reagent (Qiagen, Valencia, Calif.) according to the manufacturer’s instructions
with 1 g of the AAV3 PCR fragment and 1 g of the respective mutant plasmid.
The mutant plasmids were digested with PvuII since viral DNA is replicated
more efficiently within adenovirus-infected 293 cells if it is excised from the
vector with PvuII before transfection (34). Immediately after transfection, the
293 cells were coinfected with adenovirus dl309 at a multiplicity of infection of 4,
and virus was allowed to attach for 1 h. After attachment, virus was removed and
5 ml of Dulbecco modified Eagle medium supplemented with 2% fetal bovine
serum and penicillin-streptomycin was added. At 48 to 62 h postinfection, cells
were harvested by scraping and low-speed centrifugation. The cell pellet was
resuspended in phosphate-buffered saline and subjected to three cycles of freeze-
thawing to release the virus. The lysate was treated by incubation at 56°C for 30
min to inactivate the adenovirus. Then, 100 l of lysate was applied to the HeLa
cells with adenovirus dl309 at a multiplicity of infection of 4. At 48 to 62 h
postinfection, cells were harvested as described above, and virus was subjected to
a second passage on HeLa cells.
To test for production of recombinant AAV by using the three-plasmid trans-
fection technique (49), 293 cells were transfected by Superfect reagent (Qiagen)
with equimolar amounts of each plasmid pTR1/CMV/GFP, XX6-80 (adenovirus
helper), and each individual chimeric AAV helper plasmid.
DNA dot blot assay. The presence of DNA containing viral particles was
determined by DNA dot blot hybridization. Briefly, 10 l of each viral lysate
sample was treated with 2.5 U of Benzonase (Sigma) in 50 mM Tris (pH 8.0)–1
mM MgCl2 for 30 min at 37°C and then placed in 0.8 N NaOH–10 mM EDTA
(pH 8.0) for 30 min at 65°C to denature the samples. The samples were applied
to GeneScreen Plus (NEN, Boston, Mass.) by using a dot blot manifold. The
membrane was probed with psub201() plasmid, which had been labeled by a
random primer labeling kit (Amersham-Pharmacia, Piscataway, N.J.).
Gel electrophoresis and immunoblotting. Total protein from transfected (T)
or cycle 2 (C2) infected cells were analyzed by gel electrophoresis and immuno-
blotting. The protein concentration was determined by the BCA method (Pierce,
Rockford, Ill.). Then, 5 g of protein lysate was loaded into each lane. Proteins
were fractionated on a sodium dodecyl sulfate–10% polyacrylamide gel and
transferred to Hybond ECL (Amersham Pharmacia) by using a semidry transfer
apparatus (Bio-Rad, Hercules, Calif.). The membrane was probed with mono-
clonal antibody B1 directed against the carboxyl termini of the AAV2 VP3 capsid
protein (45). The capsid proteins were visualized by HRP anti-mouse immuno-
globulin G antibody (Sigma) by using the SuperSignal WestPico kit (Pierce) as
suggested by the supplier.
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RESULTS
Rationale of marker rescue. The three AAV2 capsid mu-
tants used in these studies are depicted in Fig. 1A, and the
details of the construction of two of them (1n532 and 1n562)
are described in Materials and Methods. One of the capsid
mutants, H/N3761, an insertion mutant described previously
(31), assembles particles that protect viral DNA but are non-
infectious due to a lack of heparin binding. The other mutants
(1n532 and 1n562) do not assemble particles but instead ex-
press truncated capsid proteins of different lengths due to
deletion and out-of-frame insertion (ln 532 and ln 562, respec-
tively) (Fig. 1A).
The marker rescue strategy is shown schematically in Fig.
1B. In this system, the above three linearized AAV2 mutant
plasmids were transfected individually into 293 cells, together
with AAV3 capsid DNA, and subsequently infected with the
adenovirus type 5 (Ad5) dl309 helper virus. If marker rescue
occurred, then AAV3 sequences recombined into mutant
AAV2 DNA, and infectious virus will be generated. The virus
lysates from these transfections (T), which contain rescued
chimeric virus, were then passaged onto HeLa cells in the
presence of helper virus. The lysates from each cycle (C1-Cx)
were analyzed for viable recombinant virus by using a number
of techniques (DNA dot blot, Western analysis, PCR, cloning,
and sequencing).
Cycling of the H/N3761, 1n532, or 1n562 mutants. We first
carried out control experiments to determine at what fre-
quency would these mutants revert back to wild type indepen-
dent of marker rescue. To determine whether H/N3761, 1n532,
or 1n562 could revert to wild-type AAV2 after successive cy-
cles of infection in the absence of wild-type AAV3 DNA frag-
ments, each of the mutant plasmids were transfected individ-
ually into human 293 cells and then infected with Ad5 dl309.
The lysates from these transfections were harvested and were
cycled two consecutive times onto HeLa cells, which express
high levels of HSP. If the H/N3761 or the 1n562 linker inser-
tion was lost or if a second site mutation developed that al-
lowed for attachment to HSP, then virus should be detected via
DNA dot blot analyses. No H/N3761 or 1n562 revertant was
ever identified after two consecutive cycles on HeLa cells (Fig.
2A, H/N3761 lanes and 1n562 lanes) as determined by DNA
dot blot analyses. The 1n532 mutant is more deleterious than
the other two mutations, since in addition to inserting a linker
at position 522, this mutant also carries a 5-bp deletion. The
only way for a viable revertant to arise from this plasmid
substrate is for the virus to gain foreign sequences from plas-
mid, cellular, or from adenovirus DNA. No revertant was de-
tected in this instance, also as judged by dot blot analyses (Fig.
2A, 1n532 lanes).
H/N3761 has previously been shown to produce capsid pro-
tein, form capsids, but not bind HSP or infect cells (31). There-
fore, it was expected that the VP1, VP2, and VP3 proteins
might be detected after transfections into 293 cells. VP3 pro-
tein was detected by Western blot analysis, as predicted (Fig.
2B, lane 1). VP1 and VP2 were detected with a longer expo-
sure of the same gel (data not shown). Importantly, capsid
proteins were not detected after two consecutive cycles on
HeLa cells (Fig. 2B, lane 7) supporting the DNA dot blot data.
With respect to 1n532 and 1n562 mutants, capsid components
were not detected after transfection (Fig. 2B, lanes 2 and 3) or
after two consecutive cycles on HeLa cells (Fig. 2B, lanes 8 and
9). As predicted, capsid proteins were not produced from these
mutants in Western blot analyses since the truncations are at
positions 532 and 564, respectively, and the antibody used, B1
(45), maps to a region downstream of the truncation.
Marker rescue of H/N3761, 1n532, and 1n562 with AAV3
PCR fragments. Marker rescue experiments were performed
to determine whether AAV3 capsid DNA fragments could
rescue the H/N3761, 1n532, or 1n562 mutants. In these exper-
iments, 293 cells were cotransfected with each of the mutant
plasmids and AAV3 PCR fragments and then infected with
Ad5 dl309. In each instance, protected viral DNA was detected
from transfection and cycling lysate for each mutant (Fig. 2A,
AAV3 row), indicating rescue of viable virions.
Capsid proteins were detected from H/N3761 transfection
lysates but not from the 1n532 or the 1n562 transfection lysate
(Fig. 2B, lanes 4 to 6), at least to the level of detection by our
Western blot analysis. Although full-length capsid proteins
from recombinants were not detected in the Western blot
analyses of the transfection lysates, obvious DNA rescue took
place at this step since viral capsid proteins were detected from
each mutant after cycling on HeLa cells (Fig. 2B, lanes 10 to
12).
Together, these results indicated that AAV3 DNA se-
quences were able to rescue the defect of these three different
AAV2 capsid mutants to produce viable AAV2/AAV3 chi-
meric viruses able to infect HeLa cells.
DNA sequence analyses of the AAV2/AAV3 chimeric virus.
In order to determine the DNA sequence of the AAV2/AAV3
chimeric virus, PCR analyses was performed on viral lysates
from several independent marker rescue experiments. PCR
was performed on two samples from H/N3761 (Fig. 3, lanes 1,
2, 7, and 8), three samples from 1n562 (Fig. 3, lanes 3 to 6, 9,
and 10), and one sample from the 1n532 marker rescue exper-
iments (Fig. 3, lanes 11 and 12). Lysates from the second cycle
(C2) on HeLa cells from each of these experiments were am-
plified with either the AAV2-specific primers (Fig. 3, odd-
numbered lanes) or the AAV3-specific primers (Fig. 3, even-
numbered lanes); see Fig. 1A for approximate location of the
primers. The specificity of the primers was verified by ampli-
fication of AAV2 or AAV3 plasmids (Fig. 3, lanes 13 to 16).
As can be seen in Fig. 3, a 2.2-kb fragment from the lysates
of all marker rescue experiments was amplified by the AAV2
primer pair, indicating that a region of AAV3 recombined into
the AAV2 mutants. In one experiment the AAV3 primer pair
was able to amplify a 2.2-kb fragment from the lysate. This
indicated that at least for one example a mixed virus popula-
tion was present (Fig. 3, lanes 3 and 4). Direct sequencing of
the PCR products suggested that a diverse mixture of chimeric
viral DNA had been produced (data not shown).
To confirm that a diverse mixture of AAV2/AAV3 chimeras
was present, an AAV helper shuttle vector was designed so
that all PCR products could be readily cloned (Fig. 3). This
shuttle vector was engineered to contain a unique AflII site
near the beginning of the capsid gene and a unique NotI site
after the end of the capsid gene facilitating cloning of all PCR
products directly into an AAV helper plasmid for sequencing
and vector production.
Both restriction enzyme and DNA sequencing analyses iden-
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tified four classes of AAV2/AAV3 chimeras (Fig. 4). Class I
chimeras contained the 5 region of the AAV2 capsid gene up
to nt 180, with the remainder of the capsid gene entirely made
up of AAV3 sequences. Class II mutants contain 5 AAV3
sequences, encompassing the mutation site, and then a pre-
ferred crossover to AAV2 sequences, 3 of the mutation site, at
one of two locations (nt 2065 and 2160). Class III mutants were
the most heterogeneous and these types of AAV2/AAV3 re-
combinants resulted from crossover at different 5 and 3 lo-
cations along the capsid coding region (see Table 1 and Fig. 5).
All class III mutants covered the area of mutation. In 89
sequenced clones, we were unable to identify second any site
revertants involving AAV 3 capsid DNA. Finally, class IV
chimeras contained almost the entire AAV3 capsid sequences
(Fig. 5).
One type of class III mutants resulted from homologous
recombination of small AAV3 DNA sequences near the mu-
tation sites, flanked on either side by AAV2 capsid sequences
(Fig. 5). A 16-bp region of AAV3 (nt 1564 to 1579, based on
the AAV3 VP1) was identified as the minimal AAV3 region
necessary to rescue the defects of the AAV2 virus. For the
generation of this 16-bp AAV2/AAV3 recombinant, an 11-bp
region on the 5 end (bp 1550 to 1560) and a 20-bp region on
the 3 end of the AAV3 (bp 1580 to 1599) was identified as
crossover sites (Fig. 5). In this viable recombinant, although
the DNA sequences were different, the amino acid sequences
were identical. Importantly, some class III chimeras exhibited
amino acid differences outside of the original mutated region
(Fig. 4 and Table 1). We could not discern an overt phenotype
related to these amino acid changes on chimeric viral infectiv-
ity based on the assays described above. However, common to
all viable recombinants was the ability to regain binding activity
to HSP. We observed 100% correlation between chimeric virus
ability to bind HSP and viability, thus supporting the impor-
tance of HSP in AAV infection (40). Since previous studies
have shown that AAV DNA can efficiently cross-package into
virion shells of different serotypes (31), we assayed a number of
the sequenced recombinants for their ability to generate viable
chimeric AAV vector. Triple transfection was performed by
using 12 different chimeras as an AAV helper. In all 12 in-
stances recombinant virus was produced (Table 1). This result
suggests that the viral DNA templates packaged into the viri-
ons isolated after cycling were also capable of expressing chi-
meric capsid proteins capable of generating infectious virus.
Together, these studies indicate that marker rescue is a valid
mechanism for rescuing mutations in the viral capsid of one
AAV serotype by using fragments from another serotype. Fur-
thermore, this is an approach that may be useful in mapping
functional domains between the existing AAV serotypes, as
well in generating unique AAV vectors with serotype-specific
properties.
DISCUSSION
Due to the diversity of their biological properties, the sero-
types of AAV are important resources for the gene therapy
community. In order to develop the full potential of AAV
vectors for gene therapy applications, it is of interest to define
the capsid domains of the individual serotypes responsible for
these properties. The ability to interchange these regions
should facilitate designing AAV vectors with novel tropisms
and transduction properties.
Domain swapping via various cloning methods as a means to
exchange serotype specific properties such as receptor binding,
tissue tropism, and purification schemes has been proposed
(30). Xiao et al. identified regions of the AAV1 capsid respon-
sible for its ability to transduce skeletal muscle by systemati-
cally exchanging domains between AAV1 and AAV2. This
approach, which relied on cloning and assessing each individ-
ual construct, was successful and demonstrates the importance
of such a strategy (W. Xiao et al., submitted for publication).
We used a marker rescue system based on homologous re-
combination as an alternate method to generate chimeric
AAV vectors. One advantage to this approach is that domains
are swapped based on selection and function and not by phys-
ical maps. Three published observations indicated that this
approach was feasible. First, recombination between the sero-
types has been shown to occur in nature. A laboratory variant
of AAV, referred to as AAV6, appears to be the result of
recombination between AAV1 and AAV2, which exchange
only 71 bp (47). Furthermore, work by Senepathy and Carter in
the early 1980s established that as few as 6 nt of homology
could result in recombination between two AAV2 mutant ge-
nomes (35). Third, the known serotypes display very high de-
gree of homology when subjected to a pairwise comparison.
Serotypes 1, 2, and 3 exhibited homology in the 80% range,
whereas serotypes 4 and 5, the most divergent, exhibited ho-
mology to the other serotypes in the 60% range overall. This
homology is dispersed throughout the entire capsid genome
and thus there are numerous regions where homologous re-
combination can occur between individual serotypes.
Our marker rescue system relies on the cotransfection of an
AAV infectious clone carrying a mutation in the capsid coding
region with wild-type capsid sequences from a different sero-
FIG. 1. Overview of the experimental system. (A) Capsid mutants used in the present study. An expanded region of the AAV2 capsid DNA
sequence (nt 3760 to 3882) and VP1 protein sequence (amino acids 521 to 561) is shown. The details of the construction of the 1n532 and 1n562
capsid mutants were described in Materials and Methods. The location of the 12-bp linker insertion found in each of the mutants is in italicized.
In addition to containing the 12-bp linker, the 1n532 mutant lacks 5 nt (underlined), whereas the 1n562 mutant contains an additional 5 nt
(underlined). As a result, the 1n532 and 1n562 capsid mutants truncate at VP1 amino acid positions 532 and 562, respectively, and do not assemble
viral particles. The H/N3761 mutant has been previously described (31) and contains a 12-bp in-frame linker (encoding the amino acids AISP)
inserted at AAV2 nt 3761. The H/N3761 mutant assembles particles but is noninfectious due to a lack of heparin binding. (B) Marker rescue
strategy to generate chimeric AAV. DNA from the three mutants (H/N3761, 1n532, and 1n562) was digested with PvuII and cotransfected with
the AAV3 PCR product. After the transfection, the 293 cells were coinfected with adenovirus dl309. The lysates from the transfections (T) were
applied in two successive cycles (C1 and C2) to HeLa cells and then infected with adenovirus dl309. The resulting viruses were analyzed by dot
blot, Western blot, PCR, and DNA sequencing analyses.
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type (Fig. 6A), followed by coinfection with adenovirus. The
homology that exists between the AAV DNA of the different
serotypes allows for homologous recombination to occur re-
sulting in, at the transfection stage, a mixed population of
chimeric viral genomes. The chimeric capsid DNA can be PCR
amplified at this step was cloned into the shuttle vector
(pxr2AN), and then this library of recombinants (Fig. 6B) can
be examined for biological properties similar to the approach
described by Xiao et al. (submitted). Alternatively, the trans-
fection lysate can be cycled onto any cell type of interest as a
selection step (Fig. 6C). The cell type utilized has an important
bearing on the types of chimeras observed (e.g., AAV2 chi-
mera that is not dependent on heparin sulfate receptor). In
addition to selection on specific cell types for novel capsid with
new tropism, direct infection of animals (Fig. 6D) with this
library and screening of individual tissues for dominant chi-
meric virus can be carried out. Whether the library is cycled
onto tissue culture cells or animals, it serves the same purpose
of enriching for the predominant viral recombinant (Fig. 6E).
A similar approach was successfully used for phage display
libraries in order to help identify tissue-specific targeting li-
gands (4).
In the present study we describe the use of serotype 3 DNA
to rescue defects in an AAV2 capsid. To carry out this study,
we used three different mutants of the AAV2 capsid. One
mutant (previously described) was capable of producing intact
viral particles but was unable to infect cells due to a lack of
heparin binding (31). The other two mutants produce trun-
cated capsid proteins and were unable to produce AAV viri-
ons. The mutated templates were composed of a 4-amino-acid
insertion (H/N3761), out-of-frame deletion (1n532), and out-
of-frame duplication mutations (1n562). Our approach al-
lowed for the selection of virus that would be viable and pro-
duce moderate to high yields. Specifically, the selection relied
on recombinants that were viable after a cycling step on human
cells expressing heparin sulfate. Because AAV2 and AAV3
appear to utilize the same receptor, we readily isolated viable
recombinants that regain heparin sulfate binding. The feasibil-
ity of this approach was demonstrated via dot blot, Western
blot, cloning, and sequencing.
We predicted and obtained four classes of chimeras based
on the regions of crossover. The smallest viable recombinant
contained only 16 nt, whereas the largest span the entire 2.2-kb
fragment of type 3 capsid sequences. These examples show the
diversity that can be generated by using this approach. Al-
though it was difficult to assess the exact crossover point in the
chimeras due to stretches of homologous sequences, some of
these recombinants exhibited differences only at the DNA level
FIG. 2. (A) Dot blot hybridization of the H/N3671, 1n532, and 1n562 mutants. 293 cells were transfected (T) with each of the mutant plasmids
(H/N3761, 1n562, or 1n532) and with (AAV3) or without (AAV3) AAV3 capsid DNA fragments and then infected with dl309. The lysate from
each was subjected to two rounds of cycling onto HeLa cells (C1 and C2). Then, 10 l of freeze-thaw lysates from the transfection (T), cycle 1 (C1),
or cycle 2 (C2) of H/N3761, 1n532, or 1n562 were applied to GeneScreen Plus membrane and probed with the psub201() plasmid, which had
been random prime labeled. (B) Analyses of the capsid protein composition from cellular lysates. Protein lysates from the transfection of H/N3761
(lane 1), 1n532 (lane 2), and 1n562 (lane 3); the cotransfection of AAV3 capsid DNA fragments with H/N3761 (lane 4), 1n532 (lane 5), and 1n562
(lane 6); or lysates from each of the above transfections which had been cycled twice (C2) onto HeLa cells (lanes 7 to 12) were resolved on a 10%
polyacrylamide electrophoresis gel and transblotted to a Hybond ECL membrane. The amount of total protein was determined by BCA assay, and
5 g of total protein was loaded per lane. The membrane was probed with monoclonal antibody B1 directed against the carboxyl termini of the
AAV2 VP3 capsid protein (45). The locations of VP1, VP2, and VP3 capsid proteins are indicated.
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(based on redundancy of the genetic code), whereas others had
changes at the nucleic acid level that resulted in chimeric
protein. Of the 89 clones isolated and sequenced, only 1 re-
combinant (class I) was composed of a 5 type 2 sequence (60
amino acids), followed by the remainder of type 3 coding
sequences. A significant number of recombinants (38 of 89,
class II) carried the 5 portion of type 3 spanning the AAV 2
capsid mutated sites, followed by a 3 portion that was type 2
DNA. In a number of these isolates, we observed break points
that clustering around nt 2060 and 2160. These preferred
crossover points were also observed with class III recombi-
nants, which were distinguished by 5 and 3 ends uniquely type
2 DNA with various portions of type 3 DNA recombined
between these sequences. After thorough analysis, the prefer-
ence for the 3 crossover point was most likely due to the fact
that this region contained the largest stretch of homology be-
FIG. 3. PCR analyses of rescued virus from independent marker rescue experiments. (Top) PCR analyses were performed on two independent
samples from H/N3761 (lanes 1, 2, 7, and 8), three independent samples from 1n562 (lanes 3 to 6, 9, and 10), one sample from the 1n532 marker
rescue experiments (lanes 11 and 12), AAV2 plasmid (lanes 13 and 14), and AAV3 plasmid (lanes 15 and 16). Lysates from the second cycle (C2)
on HeLa cells from each of these experiments were amplified with either AAV2-specific primers (lanes 1, 3, 5, 7, 9, 11, 13, and 15) or AAV3-specific
primers (lanes 2, 4, 6, 8, 10, 12, 14, and 16). The location of the 2.2-kb PCR product is indicated by an arrow. (Bottom) Diagram of the pxr2AN
shuttle vector. This shuttle vector is a modification of the pxr2 vector generated by Rabinowitz and Samulski (30), except that AflII and NotI sites
flanking the capsid regions were engineered to facilitate cloning of PCR products.
FIG. 4. Four classes of AAV2/AAV3 chimeras are produced from marker rescue experiments. The four classes of AAV2/AAV3 capsid
chimeras identified are depicted, and arrows indicate the approximate sites where homologous recombination occurred between the capsid DNA
of serotypes 2 and 3. Whether these classes were chimeras at the amino acid level is indicated next to each class. Representative AAV helper clones
from each class were all able to generate rAAV in a standard triple-transfection assay.
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tween the two serotypes (50 nt), since all of the carboxy amino
acids past this breakpoint are conserved. We also observed two
additional common crossover regions. One was located in the
5 portion of the type 2 capsid gene (nt 530), and the second
region was located immediately downstream of the mutated
region in the marker rescue template (nt 1600). Both of these
areas contained stretches of pyrimidine residues. Additionally,
the 5 crossover region was preceded by a putative small stem-
loop structure that may have influenced recombination. Over-
all, it appeared that the common break points that we observed
were consistent with homologous recombination pathways
(large blocks of homologous sequences and duplex regions
subject to melting apart). Finally, we isolated recombinants
that contained the entire 2.2-kb fragment of type 3 sequences.
These were not common isolates, although one could imagine
the advantage of replacing the entire capsid-coding region
rather than replacing mutated segments.
From the number of classes that were identified, this marker
rescue technique may be a valuable method to map or define
the domains equivalent between the different AAV serotypes.
This becomes important since only the three-dimensional
structure of AAV2 has been determined (50), and investigators
must rely on this information to predict regions of the capsid of
the other serotypes that are involved in receptor binding. The
marker rescue approach should more precisely identify amino
acid domains within the crystal framework. For example, by
using the marker rescue approach, the region or regions of
AAV4 or AAV5 responsible for sialic acid binding may be
placed in the context of AAV2 (Fig. 6) (19) In addition, as
more functional domains are identified (nuclear localization
FIG. 5. Sequence alignment of class III chimera clone 6q. Sequence of a portion of the AAV2, AAV3, and AAV2/3 chimeric clone 6q
(corresponding to AAV3 capsid open reading frame nt 1538 to 1605) is shown. A 16-bp region of AAV3 (underlined; nt 1564 to 1579, based on
the AAV3 VP1) was identified as the minimal AAV3 region necessary to rescue the defects of the AAV2 virus (the line above indicates the location
of the mutated region). For the generation of the chimeric clone 6q, an 11-bp region on the 5 end (bp 1550 to 1560) and a 20-bp region on the
3 end of the AAV3 (bp 1580 to 1599) were identified as crossover sites. The sites where homologous recombination is presumed to occur are
shown in boxes.
TABLE 1. Classes of AAV2/AAV3 chimeras characterized in this studya
Class No. of clones Subclass No. of clones Representative clone
Crossover nt
Amino acid differences Virus production
5 3
I 1 I 1 18-0 180 NA Yes (N) Yes
II 38 IIa 3 1F NA 2065 No Yes
IIb 2 NA 2160 No No
III 46 IIIa 2 5A 1541 1600 (M) No Yes
IIIb 2 1549 1600 No ND
IIIc 3 1541 1600 (M) No ND
IIId 2 17-5 208 2153 Yes (N) Yes
IIIe 1 18-C 345 2065 Yes (N) Yes
IIIf 1 18–19 530 2053 Yes (N) Yes
IIIg 1 18–42 530 2095 Yes (N) Yes
IIIh 1 18–25 530 2153 Yes (N) Yes
IIIi 1 18NN 676 1846–1921 Yes (N and C) Yes
IIIj 1 18-Z 530 2065 Yes (N and C) Yes
IIIk 2 18-43 650 2165 Yes (N) Yes
IV 4 IV 4 3-41 NA NA No Yes
a The four classes of chimeric clones depicted in Fig. 4 were placed into subclasses based on 5 and 3 crossover points. Nucleotide positions of crossover are based
on numbering beginning from VP1 and indicate the first nucleotide position of the VP1 capsid DNA that can be identified as distinctly AAV2 or AAV3. For example,
clone 17-5 is a class III chimera that contains AAV2 DNA sequences at the 5 regions, changes to AAV3 at position nt 208, and then changes back to AAV2 at nt 2153.
Whether the nucleotide differences correlated with change is indicated, and whether the amino acid differences were at the amino terminus (N) or the carboxy terminus
(C) is indicated parenthetically. Whether virus was produced from the respective vector is also indicated. NA, not applicable; ND, not determined; M, microrecom-
bination.
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domains, endosome escape motifs, packaging mutants, regions
with lipase activity, etc.) for type 2 or the other serotypes,
marker rescue should allow one to quickly map equivalent
domains in the other serotypes.
Since the method of marker rescue was first described by
Hutchison and Edgell to map DNA fragments from bacterio-
phage X (16), this technique has been used to map the func-
tions of genes from a diverse array of organisms, including
viruses, bacteria, and plants (42, 44, 51). Here the use of
marker rescue is described as a means for generating AAV
chimeras. We demonstrated the use of three AAV2 mutants as
a platform for marker rescue; however, it should be possible to
rescue a mutant of any serotype with DNA from another se-
rotype. Ultimately, a collection of chimeric viruses will be gen-
erated that should possess new phenotypes and tropism that
will significantly impact vector targeting, as well as optimal
vector transduction for human gene therapy.
While this study was in review, the crystal structure of AAV2
was published (50). Marker rescue should complement, as well
as expand, the information now being gleaned from the crystal
structure. With the crystal structure in hand and the ability to
produce viable chimeras from marker rescue-like approaches,
we should see in the near future significant contributions to
both AAV biology and vector development.
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